scholarly article | Q13442814 |
P50 | author | Clara D. Bloomfield | Q4793409 |
Richard A. Larson | Q41899936 | ||
Charles A Schiffer | Q88557115 | ||
Jonathan E Kolitz | Q90696849 | ||
Michael A Caligiuri | Q97333782 | ||
Bayard L Powell | Q114413078 | ||
John Anastasi | Q114529746 | ||
P2093 | author name string | Maria R Baer | |
Stephen L George | |||
Richard K Dodge | |||
Hans Minderman | |||
Kieran L O'Loughlin | |||
P433 | issue | 4 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | patient | Q181600 |
acute myeloid leukemia | Q264118 | ||
multiple drug resistance | Q643839 | ||
leukemia | Q29496 | ||
P304 | page(s) | 1224-1232 | |
P577 | publication date | 2002-08-01 | |
P1433 | published in | Blood | Q885070 |
P1476 | title | Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720 | |
P478 | volume | 100 |
Q35125889 | A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605. |
Q35628954 | A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia |
Q38107993 | ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. |
Q35056738 | ABC transporters: unvalidated therapeutic targets in cancer and the CNS |
Q35193725 | ATP Binding Cassette transporters associated with chemoresistance: transcriptional profiling in extreme cohorts and their prognostic impact in a cohort of 281 acute myeloid leukemia patients |
Q38234863 | Acute myeloid leukemia and myelodysplastic syndromes in older adults |
Q38026008 | Acute myeloid leukemia in older adults |
Q27851713 | Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia |
Q33905670 | Altered phospholipid transfer protein gene expression and serum lipid profile by topotecan |
Q35664332 | Analysis of the interaction of induction regimens with p-glycoprotein expression in patients with acute myeloid leukaemia: results from the MRC AML15 trial. |
Q35038054 | Cancer stem cells and side population cells in breast cancer and metastasis. |
Q36111203 | Chamaejasmin B exerts anti-MDR effect in vitro and in vivo via initiating mitochondria-dependant intrinsic apoptosis pathway |
Q37065843 | Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients |
Q41871957 | Do commonly used clinical trial designs reflect clinical reality? |
Q35946969 | Drug resistance: still a daunting challenge to the successful treatment of AML. |
Q37289691 | Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720. |
Q38887070 | Esters of the marine-derived triterpene sipholenol A reverse P-GP-mediated drug resistance. |
Q47140172 | Expression of multidrug resistance protein P-glycoprotein in correlation with markers of hypoxia (HIF-1α, EPO, EPO-R) in invasive breast cancer with metastasis to lymph nodes. |
Q27851545 | Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study |
Q34786280 | Free radical theory of autoimmunity |
Q84966141 | Generating inhibitors of P-glycoprotein: where to, now? |
Q36873270 | Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia |
Q36020057 | HG-829 is a potent noncompetitive inhibitor of the ATP-binding cassette multidrug resistance transporter ABCB1 |
Q39655929 | Image-Based Chemical Screening Identifies Drug Efflux Inhibitors in Lung Cancer Cells |
Q60171352 | Intensive consolidation therapy compared with standard consolidation and maintenance therapy for adults with acute myeloid leukaemia aged between 46 and 60 years: final results of the randomized phase III study (AML 8B) of the European Organization f |
Q33380148 | Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. |
Q34166391 | Marine sponge-derived sipholane triterpenoids reverse P-glycoprotein (ABCB1)-mediated multidrug resistance in cancer cells |
Q24612217 | Micro-RNAs and copy number changes: new levels of gene regulation in acute myeloid leukemia |
Q33758413 | Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995) |
Q34255292 | Molecular pathways: regulation and therapeutic implications of multidrug resistance |
Q34052614 | Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study |
Q38651372 | Myelodysplastic Syndromes and Acute Myeloid Leukemia in the Elderly |
Q41881090 | New treatments and strategies in acute myeloid leukemia |
Q64108677 | Novel 3,4-Dihydroisocoumarins Inhibit Human P-gp and BCRP in Multidrug Resistant Tumors and Demonstrate Substrate Inhibition of Yeast Pdr5 |
Q37495378 | Novel postremission strategies in adults with acute myeloid leukemia |
Q47129596 | Novel strategies to prevent the development of multidrug resistance (MDR) in cancer. |
Q64388331 | Oligomeric proanthocyanidins (OPCs) from grape seed extract suppress the activity of ABC transporters in overcoming chemoresistance in colorectal cancer cells |
Q34349313 | Overcoming drug resistance by regulating nuclear receptors |
Q33934534 | P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the aurora-B kinase inhibitor barasertib-hQPA |
Q34124919 | P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808 |
Q36623275 | Paclitaxel nanocrystals for overcoming multidrug resistance in cancer |
Q37338371 | Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia |
Q35849784 | Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. |
Q33750171 | Prevention of multidrug resistance (MDR) in osteosarcoma by NSC23925. |
Q38769960 | Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia |
Q50673610 | Regorafenib overcomes chemotherapeutic multidrug resistance mediated by ABCB1 transporter in colorectal cancer: In vitro and in vivo study. |
Q35584427 | Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity |
Q34774854 | Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug Resistance |
Q36414444 | Semi-synthetic ocotillol analogues as selective ABCB1-mediated drug resistance reversal agents. |
Q35847482 | Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222. |
Q30497200 | Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia |
Q38233077 | Strategies for overcoming the blood-brain barrier for the treatment of brain metastases |
Q28481389 | Synthesis of a dual functional anti-MDR tumor agent PH II-7 with elucidations of anti-tumor effects and mechanisms |
Q37199950 | Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin |
Q42118010 | Targeting leukemia stem cells: The new goal of therapy in adult acute myeloid leukemia |
Q36680180 | Targeting tumor microenvironment with PEG-based amphiphilic nanoparticles to overcome chemoresistance |
Q28535342 | The FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactions |
Q37289700 | The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms |
Q90113477 | The Pyrazolo[3,4-d]pyrimidine Derivative, SCO-201, Reverses Multidrug Resistance Mediated by ABCG2/BCRP |
Q27014790 | The clinically relevant pharmacogenomic changes in acute myelogenous leukemia |
Q37941758 | The controversial role of ABC transporters in clinical oncology. |
Q37195803 | The feasibility of inpatient geriatric assessment for older adults receiving induction chemotherapy for acute myelogenous leukemia |
Q37002357 | Therapeutic implications of leukemic stem cell pathways |
Q34597777 | Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients |
Q37301691 | Tomorrow's cancer treatments today: the first 50 years of the Cancer and Leukemia Group B. |
Q37129807 | Treatment resistance mechanisms of malignant glioma tumor stem cells |
Q33579371 | Ubc9 expression predicts chemoresistance in breast cancer |
Q41889792 | Using rhodamine 123 accumulation in CD8 cells as a surrogate indicator to study the P-glycoprotein modulating effect of cepharanthine hydrochloride in vivo |
Q34360283 | Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999 |
Search more.